Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
105 GBX | +1.94% | +5.00% | +22.24% |
Mar. 27 | Sainsbury's, Petershill Partners upped to 'buy' | AN |
Mar. 18 | Exane raises Rentokil; RBC cuts Centrica | AN |
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.91 for the current period. Therefore, the company is undervalued.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company does not generate enough profits, which is an alarming weak point.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Life & Health Insurance
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+22.24% | 1.33B | C+ | ||
+16.17% | 79.51B | B- | ||
+8.03% | 50.22B | B+ | ||
+2.52% | 48.11B | B | ||
+10.08% | 42.2B | B+ | ||
+7.93% | 39.71B | B+ | ||
+20.13% | 37.78B | B | ||
+2.59% | 30.07B | B | ||
-7.73% | 27.56B | B- | ||
-17.06% | 24.71B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- JRP Stock
- Ratings Just Group plc